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Inflammatory bowel disease (IBD) including Crohn’s disease (CD) and ulcerative 
Colitis (UC) are immune mediated chronic disorders. IBD may manifest at any age and 
persists in most cases lifelong. The primary aim of treating pediatric patients with 
inflammatory bowel disease (PIBD) is to achieve early remission, to prevent relapses, 
to reduce side effects of therapy to allow children and adolescents a regular physical 
and psychosocial development without developing any disease complications. 
Nevertheless, disease complications can occur in pediatric IBD (PIBD) patients at any 
time. 
This thesis focuses on frequent and severe complications in PIBD patients, such as 
perianal fistulizing disease and impaired bone health and growth. At the Division of the 
Dr. von Hauner Children’s Hospital- at the Ludwig Maximilian University (LMU) in 
Munich, approximately 150 to 170 children with IBD are under continuous care and 
followed until transferred into adult care. Most of these children are included in a 
registry for PIBD patients living in Germany or Austria. 
CEDATA registry, established in 2004 by members of the Society of Pediatric 
Gastroenterology and Hepatology (GPGE) of German speaking countries collects 
longitudinal data of PIBD patients. This register supports quality reviews of IBD care 
and evaluates differences in IBD treatment and management within Germany and 
Austria. It also offers the opportunity to answer remarkable research questions. I was 
fortunate to collaborate and to analyze data from the CEDATA registry on the 
prevalence and incidence rate of perianal disease in Crohn’s disease patients in a 
large PIBD cohort. During the years as PhD student under the supervision of Professor 
Dr. med Sibylle Koletzko I was privileged to work with my talented colleagues, Dr. med. 
Klara Frivolt and PD Dr. med. Tobias Schwerd on a prospective controlled intervention 
study investigating the effects of partial enteral nutrition on bone health, geometry and 
growth in children with quiescent pediatric Crohn’s disease.   
During the course of my PhD, I also contributed to an international multicenter study 
(ImageKids) with the aim to develop and validate two indices capable of measuring 
intestinal damage and inflammatory disease activity in Pediatric Crohn's disease by 
means of Magnetic Resonance Imaging (MRI) with Enterography protocol (MRE) and 
pelvic MRI. All participants underwent magnetic resonance enterography and 
ileocolonoscopy at baseline and after six months. Fecal samples were collected in this 
cohort to evaluate other fecal inflammation biomarkers in comparison to the 
established measurement of calprotectin concentrations.  
Controlling disease activity is essential to reduce IBD complications. Optimizing 
treatment strategies with drug monitoring became an integral part of the current 
treatment strategies [1, 2]. In 2016, our division received funding from the European 
Union within the HORIZON 2020 program for a large project called PIBD Network for 
Safety, Efficacy, treatment and Quality improvement of care (PIBD-SETQuality). The 





stratified into low and high risk groups. The aim was to evaluate the efficacy of 
methotrexate in comparison to azathioprine (low risk) or adalimumab (high risk). Within 
this international consortium, we were in charge for the work package on drug 
monitoring and safety.  Throughout my doctoral thesis, I wrote the standard operation 
procedures and coordinated the measurement of drug trough levels and metabolites, 
monitored all study subjects from the different centers and suggested adjustments 
where necessary. The project had been extended until June 2021. Further publications 
will result from this project.  
The publications presented in this thesis are based on two with first authorship 
conducted under the supervision of Prof. Dr. Sibylle Koletzko, PD Dr. Jan de Laffolie, 
Dr. Katharina Werkstetter and PD Dr. Tobias Schwerd. In two further publications, not 
considered in this thesis, from the ImageKids project I have served as a co-author (see 
publication list).  
1.1 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) comprises patients with chronic relapsing bowel 
inflammations defined as Crohn’s disease (CD), ulcerative Colitis (UC) and Colitis 
indeterminata (CI), later has been renamed as IBD-unclassified (IBD-U) [3]. Burrill B. 
Crohn firstly described Crohn’s disease histological findings in 1932 [4]. The 
pathogenesis of IBD is multifactorial, covering genetics, environmental factors, 
dysregulated immune response and intestinal microbiome [5]. Sartor et al. describe 
the etiology of IBD as followed: “The onset and reactivation of IBD are triggered by 
environmental factors that transiently break the mucosal barrier, stimulate an immune 
response or alter the balance between beneficial and pathogenic enteric bacteria [6].”  
IBD may manifests at any age in up to one-fourth of affected patients it develops before 
reaching adulthood. Pediatric onset IBD (PIBD) differs from adult onset IBD in some 
aspects: (1) disease phenotype, (2) progression of disease and (3) disease 
complications (table 1, fig 1). This thesis will mainly focus on Crohn’s disease. The 
dynamic features of PIBD (disease location and behavior, severe complication) have 
been addressed in the new Paris classification. The known Montreal disease 
classification was modified in Paris in 2011 and included a new sub-group for children 
<10 years (A1a) [7] [8] (table 1). The higher risk of monogenic disorders among the 
very young IBD patients has resulted in further sub-classification based on age at 
diagnosis:  <6 years of age has been labeled as very early onset IBD (VEO-IBD),  <2 





Table 1: IBD classification according to age of onset 
IBD groups according to age Classification Age of onset in years 
Pediatirc IBD onset Montreal A1 <17  
Pediatirc IBD onset Paris A1b 10-17 
Early onset-IBD Paris A1a <10 
Very early onset- IBD   <6 
Infantile IBD  <2 
 
(1) Disease phenotype: Pediatric CD (PCD) often presents with predominant 
involvement of the colon and rectum, whereas adults with CD frequently have ileocecal 
affection [8, 11]. Figure 1 shows CD phenotypes according to the Paris classification 
(L1-L4) [8, 12]. (2) Disease progression:  PCD indicates a more diffuse and extensive 
phenotype and suffers from a stronger progression of disease compared to adults [8, 
13]. Long diagnostic latency is prevalent among VEO-IBD patients. These patients 
appear to have the most severe disease course and more complications during 
childhood [10, 14]. (3) Disease complications: PCD patients experience complications 
more often during disease progress compared to adults with IBD [3, 15]. A high 
proportion of CD patients are affected by delayed puberty and impaired growth (G0/G1, 
fig. 1) [11, 12, 15]. The Paris classification, shown in figure 1, includes stricturing, 
fistulizing and perianal disease (PD). Children are more affected by fistulizing and 
perianal disease than adults [16]. Our working group at Dr. von Haunersche Children’s 
hospital had particular interest in bone health in PIBD. Newly diagnosed PCD patients 
present with reduced trabecular bone density, disturbed bone geometry, muscle mass 
and compensatory increased cortical density resulting in an increased risk for 











Figure 1: Buderus S. et al. (2015 Dtsch Ärzteblatt) Paris Classification of CD 
 
1.1.2 Epidemiology of pediatric IBD 
A steady increasing incidence rate of IBD has been found in the last century in 
industrialized and industrializing countries (fig. 2) [5]. IBD became a global disease 
with the highest prevalence in western countries (starting in the 19th century). However, 
industrializing countries or newly industrialized countries from Asia, Middle East, Africa 
and South America reported a highly dynamic increase of IBD incidence within the last 
decades (starting in the 20th century) [5, 19]. A peak of IBD incidence rate is found at 
the age of 33 years [20]. 
 
Figure 2. Kaplan G. et al (2017 Gastroenterology): Increasing trend of IBD in 







Since the beginning of the 21st century, population-based studies have shown that IBD 
incidence stabilizes among adults [21-23]. However, pediatric epidemiological data 
indicates a further steady increase in incidence and prevalence of CD in industrialized 
and industrializing countries, while the incidence in pediatric UC mostly remained 
stable in recent decades [5, 21, 24]. IBD develops before reaching the age of 18 years 
in up to 20% of IBD patients and out of these 25% are younger than 10 years at initial 
diagnosis. Age at onset less than 6 years (VEO IBD) has been reported in 15% of PIBD 
patients and present the fastest growing incidence rate age group [25, 26].  
A systematic review from Benchimol et al. in pediatric IBD between 1950 and 2009 
showed significantly increased incidence rates of CD in in 15 out of 25 studies and UC 
in in 4 out of 20 studies. A French study based on insurance data of children and adults 
reported incidence rates with 8.2/100.000 for CD [27]. Pediatric incidence rates of IBD 
from Stockholm (2002-2007) reported 12.8/100.000 new IBD cases (9.2/100.000 for 
CD) [28]. Based on German insurance data from 2007-2012, applying the same 
methodology and definition as Benchimol et al. in a Canadian study [21], Wittig et al. 
reported high IBD prevalence and incidence rates in the literature with 64.62/100.000 
and 17.41/100.000, respectively [29]. Figure 3 presents the rising incidence rate of IBD 
with age. This German epidemiological data from 2012 are higher compared to 
previous data and to other European countries [12, 20]. The time trend and the most 
recent data collected on the incidence and prevalence of IBD could explain the higher 
rates compared to older studies. Country differences may also be explained by 





Figure 3: Wittig R. et al (2019 JPGN): German PIBD Incidence rate in 2012 per 100.000 
insured patients at Barmer GEK 
 
 
1.1.3 Etiopathogenesis of PIBD 
The worldwide increasing incidence supports the concept of IBD being a multifactorial 
disease within interplay of environmental, genetic and immunological factors. Several 
environmental factors for PIBD development have been identified so far and include 
westernized diet, absence of breastfeeding, antibiotic intake during the first years of 
life and vitamin D levels. Diet induces shifts in the intestinal microbiome and 
metabolome with direct and indirect influences on the immune response and on the 
barrier function [30, 31]. Genetic risk loci: several genetic variants/risk loci have been 
identified with risk increasing or reducing effect on IBD. The variants influence the 
innate and adaptive immune system causing immune dysregulations [32]. Although 
the etiology of IBD has not been fully understood yet, it involves a complex interaction 
among environmental factors, microbiome, genetics and immune response in 
individual patients. The contributing risk factors for the development of IBD are 






Figure 4: Kaplan G. et al (2017 Gastroenterology): Etiology and contributing risk factors 
for PIBD  
 
1.1.3.1 Genetics 
Genetic IBD risk loci: Twin studies and family history have shown that Crohn’s disease 
and Ulcerative Colitis have heritable components [33]. In monozygotic- twins, CD has 
a concordance rate of 20%-50% compared to 10% in dizygotic twins. Ulcerative Colitis 
shows lower values, 15% for monozygotic and 5% concordance for dizygotic twins 
indicating a weaker heritable component for UC [34]. NOD2/CARD15 is the most 
essential and well-known genetic risk gene in IBD that increases the risk for CD 










encodes a protein that is involved in recognizing bacteria by cells in the innate immune 
system [36, 37].  Genome-wide studies identified more than other 200 IBD risk loci up 
to date. Some of them affect the innate and adaptive immune response, endoplasmic 
reticulum stress, intestinal barrier function and microbial homeostasis [38-41]. The 
understanding of why some IBD-associated risk gene carriers remain healthy while 
others develop IBD remains unclear. VEO-IBD children often present severe disease 
progress, which may be refractory to standard treatment. Whole- exome analyses in 
parents and affected children revealed that among patients with VEO IBD monogenetic 
disorders may occur in up to 20% of cohort. About 60 different monogenetic disorders 
have been identified, which may manifest with IBD like clinical picture [9, 42-45].  
1.1.3.2 Environmental risk factors 
Migrant studies indicate the importance of environmental factors in the pathogenesis 
of IBD and support the hypothesis that Westernized lifestyle, diets, and especially early 
life events in childhood (breastfeeding, antibiotic use) influence IBD development [46, 
47]. Population-based cohort- and case- studies investigated the following aspects of 
environmental factors. 
Westernized lifestyle: Differences in nutrition and health status exist between different 
countries and within a country between rural and urban populations. Urban cities involve 
greater food abundance, less physical activity, and psychosocial stress compared to rural 
lifestyle [48]. The previously mentioned increasing incidence of IBD, especially in industrialized 
countries, indicates the Western lifestyle and the changes associated with industrialization 
need to be considered as risk factors for IBD [46, 49].  
Westernized diet, including consumption of high animal protein, red meat, fat, processed 
foods, and refined sugar intake, is positively associated with the risk of IBD [50-53]. Regular 
consumption of fast food increases the risk for IBD, which could be related to mono- and poly-
unsaturated fatty acids [54, 55]. Whereas plant fibers, particularly plantain, broccoli and 
Mediterranean diet, including fruits, vegetables, fish, and olive oil has been associated with 
reducing risk for IBD development [5, 47, 56]. Overall, diet shapes the composition of the 
intestinal microbiome and therefore the immune response [56, 57]. Recommendations for IBD 
diets include Mediterranean-diet, avoiding processed food, refined sugar, fast and highly 
processed food, and saturated animal fat [56]. The newly established Crohn’s disease 
exclusion diet (CDED), is discussed in chapter 1.6.1.1 and paper II [47, 50, 58]. 
Breastfeeding: In 2017, a systematic review and meta-analysis of 35 studies showed 





0.59‒0.85), (OR, 0.78; 95% CI, 0.67‒0.9) and (OR, 0.74; 95% CI, 0.66‒0.83), respectively [59, 
60]. The positive effect of breastfeeding might be explained by supporting the development of 
the immune system and the intestinal microbiome with long-term effects on later health and 
disease [60, 61].  
Antibiotics: The use of antibiotics during childhood increases the risk of developing IBD 
in Western countries. This effect increases with younger age at the first antibiotic 
exposure and multiple episodes of intake [62, 63].  Lewis et al. reported that early 
exposure to antibiotics increases microbial dysbiosis of the intestine, while reduced 
inflammation is associated with reduced dysbiosis [64].  
Vitamin D: Low vitamin D levels are considered as a risk factor for developing initial IBD or 
relapses [47]. In particular, vitamin D deficiency increases hospitalization, relapses and use of 
escalating treatments in IBD patients. Vitamin D showed protective effects as potential immune 
modulator for IBD patients and should be monitored and supplemented if needed [65, 66].  
1.1.3.3 Microbiome 
The microbiome differs between healthy patients and patients affected by IBD [67]. However, 
this may be a secondary effect due to the inflammation. IBD treatment and special diets that 
induce remission pursue a shift in the intestinal microbiome [31, 67, 68]. Schwerd et al. from 
our group have shown that 6-8 weeks of treatment with exclusive enteral nutrition (EEN), a 
liquid nutritional complete formula, reduces alpha diversity and influences a shift in bacterial 
colonization [67]. The reduction in bacterial richness and lower alpha diversity induced by EEN 
is most likely caused by the absence of dietary fibers and fermental carbohydrates [69-71]. 
Data from our partial enteral nutrition (PEN) paper (Paper-II) will show that PEN is not sufficient 
to cause changes in the structure of the microbial community, as 6 to 8 week EEN treatment 
driven intestinal microbiome shifts in CD patients. Several other studies have also proven that 
diet affects the intestinal microbiome [72-74]. Figure 5 of Tilg et al. shows an interaction 
between healthy food intake, host immunity and the intestinal microbiome that starts in early 
childhood. Westernized diet, enriched in fat, phosphatidylcholine and L-carnitine activate 
intestinal inflammation by influencing the microbiome [75]. The intestinal microbiome is altered 






Figure 5: Tilg H. et al. (2015 Gastroenterology) Interactions of food and microbiome 
 
1.1.3.4 Immune dysregulation 
Diets and EEN effects potential interactions between immune responses and the 
intestinal microbiota [67, 78]. The colon epithelium and its mucus layer may get irritated 
by so far “unhealthy” (mainly unknown) nutrients and allow invasion and translocation 
of non-pathogenic bacteria or bacterial antigens that replicate within epithelial cells, 
dendritic cells, and macrophages and trigger the immune response and inflammation 
[78]. Westernized diet with nutrients including sodium caprate, gliadin, emulsifiers or 
carboxymethylcellulose, may affect the tight junctions in the epithelial layer and 
increase bacterial growth and translocation, whereas fibers reduce the risk for bacterial 
translocation and overgrowth [79, 80]. Alterations in susceptibility genes might lead to 
cell dysfunction, allowing bacteria to cause this imbalance due to loss of bacterial 
eradication and loss of epithelial integrity and increased penetration of bacteria leading 
to a vicious cycle of inflammation [81, 82]. 
1.4 Clinical manifestation  
Classic gastrointestinal symptoms in PIBD involve abdominal pain, diarrhea (with or 
without blood), weight loss, decreased height-velocity, lack of energy, anorexia, 
anemia and/or perianal disease [15, 83, 84]. Extra-intestinal manifestations (EIM) 
involves arthropathy (peripheral and axial association), stomatitis, erythema nodosum, 
pyoderma gangrenosum, primary sclerosing cholangitis, pancreatitis, hepatobiliary or 





are associated with increased baseline disease activity [85-87]. The incidence rate of 
EIM after diagnosis was 9% at 1 year, 19% at 5 years and 29% at 15 years [86]. EIM 
at childhood onset CD is more frequent compared to adult onset CD (8.5% vs 5.0%) 
[87] [88]. 
1.4.1 Complications 
Children and adolescents with IBD often develop a more complicated disease course 
compared to adult patient. The following sub-chapters will focus on three main 
complications during the PIBD disease course, which are further discussed in Paper I 
and Paper II.  
1.4.1.1 Perianal disease  
Perianal disease includes perianal abscess and/or fistula. In CD patients, PD is a 
common complication that may lead to the initial CD diagnosis, whereas PD rarely 
affects UC (94% vs 6%, respectively) [89]. PD occurs more often in male PIBD patients 
than in females and children with PD tend to have a more severe disease progress 
[89, 90]. The prospective EuroKids registry initiated by the European Society of 
Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), documents 
manifestation of PIBD at the time of diagnosis in more than 3000 pediatric patients and 
revealed a 9 % prevalence of abscess and perianal fistula at diagnosis of CD [91]. The 
PIBD Collaborative Research Group from the United States and Canada reports 
similar findings with a 10% occurrence of PD at CD diagnosis (N=247) [92]. The 
incidence of PD in pediatric CD patients has been reported in a large IBD cohort by 
Adler et al. (N=1399), with an incidence rate of 13.6%, 21.6% and 26.1% at 1, 3 and 5 
years after diagnosis, respectively [90].  
PD treatment and management depends on its type and severity and includes 
conservative management (antibiotics and/or initiating immunomodulators/ biologics), 
and/or surgical management (fission or drainage/leash) [93]. Moderate to severe 
fistulizing CD can effectively be treated with combined management (conservative 
(anti-TNF-alpha initiation) and surgical) [94, 95]. Higher trough levels of Infliximab (IFX) 
with ≥10.1 mcg/mL have been associated with favorable fistula response [94, 96]. PD 
treated with Adalimumab induced perianal fistula closure within 12 weeks of treatment 





data, management of PD and risk factors for developing PD will be discussed in Paper 
I of this thesis. 
1.4.1.2 Growth failure  
Growth retardation and pubertal delay in PIBD patients is a well-known complication. 
The incidence of growth delay at diagnosis is more common in pediatric CD patients 
compared to UC, 15-40% versus 3-10%, respectively [24, 97]. Causative factors for 
growth failure are malnutrition, undernutrition, delayed puberty with decreased 
secretion of sexual hormones, and the inflammation itself. The prospective European 
study of newly diagnosed CD patients with long-term follow up (GROWTH study) 
published a trend for better height z-scores after 2 years in patients initially treated with 
EEN compared to steroids as initial induction therapy [98].  Other studies confirm that 
the use of exclusive enteral nutrition (EEN) compared to corticosteroids as induction 
therapy significantly improves the nutritional status and growth in PCD patients [99]. 
Besides EEN, anti-TNF biologics have been associated with improved growth [100, 
101]. Controlling CD inflammation stabilizes or improves linear growth, in particular 
when compared to corticosteroid-treated patients [98, 102]. Further supporting factors 
for improving growth in PCD patients with quiescent disease will be discussed in Paper 
II of this thesis. 
1.4.1.3 Bone health  
Impaired bone health is a common complication at PIBD diagnosis attributed to 
decreased muscle mass, low physical activity, ongoing inflammation or nutritional 
deficiencies [103]. PIBD patients often present reduced trabecular density, high, 
cortical bone density, disturbed bone geometry and decreased muscle mass at 
disease onset. CD patients might have an increased risk for osteopenia and bone 
fractures [17, 18, 103]. Our working group at the Dr. von Hauner Children’s hospital 
has shown that 8 weeks of induction treatment with EEN improved bone health in CD 
patients with active disease, three months after starting EEN [104]. Avoiding systemic 
steroids and controlling inflammation by e.g. anti-TNF therapy improves bone density 
and structure in PCD with greatest effect in younger patients at early stage of puberty, 
suggesting a window of opportunity for treatment of bone deficits [105]. Bone health, 
bone geometry and muscle mass status in patients who have entered remission has 





1.5 Diagnostic work-up 
According to ESPGHAN guidelines, a complete diagnostic workup for initial IBD 
diagnosis includes the performance of physician examination; laboratory workup, 
upper and lower endoscopy and small bowel imaging such as Magnetic resonance 
enterography (MRE) or video capsule endoscopy (VCE)) [106].  
1.5.1 Diagnostic work up: laboratory 
Laboratory workup for IBD patients in the blood includes the following parameters: 
complete blood count, C-reactive protein (CRP) and erythrocyte sedimentation rate 
(ESR) as main inflammatory markers and for exclusion of thrombocytosis, 
leukocytosis, and anemia. Low serum albumin indicates severe ulceration with protein-
losing enteropathy or lymphatic loss due to stricture. Antibodies to Saccharomyces 
cerevisiae (ASCA IgA and IgG) are markers for CD with a high specificity but low 
sensitivity. They are frequent positive in patients with early disease onset [107]. 
Laboratory workup for children in feces includes always the exclusion of intestinal 
infections including with Clostridium difficile.  Fecal calprotectin is a marker for 
intestinal inflammation, but not specific for IBD. Fecal calprotectin (FC) is a neutrophil 
dominating and calcium- and zinc-binding protein in feces, which releases during 
active colorectal inflammation [108]. FC test is used for the diagnostic and monitoring 
of IBD [109]. It shows excellent results compared to endoscopic findings with a cut off 
<68 µg/g to distinguish IBD from other non-inflamed gastrointestinal conditions [110]. 
FC diagnostic has a high sensitivity (96%-98%) and modest specificity (69%- 72%) 
[111-113]. The recommended FC cut off level for children >4 years and adults for an 
increased value is >50 µg/g [114-116].  
1.5.2 Diagnostic work up: Endoscopy  
The IBD Working Group of the European Society for Pediatric Gastroenterology, 
Hepatology, and Nutrition developed consensus guidelines for a full diagnostic workup 
of pediatric IBD patients, called the Porto criteria that were published in 2014 [3]. In 
order to evaluate intestinal inflammation the diagnostic Porto criteria include 
esophagogastroduodenoscopy (EGD), ileocolonoscopy and MRE for small bowel 
assessment [3, 91]. ESPGHAN guidelines recommend to take at least two 
representative biopsies from inflamed areas, as well as five from defined colonic areas 





biopsies from terminal ileum regardless the macroscopy is normal or not, during 
ileocolonoscopy [91, 117]. The EuroKids registry gathered data on the completeness 
of the initial diagnostic work up with the different participating sites between 2004 and 
2009.  EGD and ileocolonoscopy were performed in 64% of all cases (N=2087) and 
increased steadily over time (year 1 of the registry (52 %) to year 5 (71%, P < 0.001)) 
[91]. 
1.5.3 Diagnostic work up: Imaging Small Bowel 
Magnetic resonance enterography (MRE) is preferred in PIBD over computer 
tomography for high diagnostic accuracy and absence of radiation. MRE requires an 
oral intake of a large volume of contrast agent [118]. The aliquots are ingested over 
one hour before the scan [119, 120]. The bowel preparation and scanning techniques 
are heterogenic according to a meta-analysis [121]. Contrast agents are positive, 
negative, or most frequently biphasic. The latest provides good contrast between the 
bowel lumen and wall-thickness on both T2- and enhanced T1-weighted images and 
improves the detection of signal changes and enhancement of an inflamed bowel 
[122]. A meta-analysis from Giles et al. reported a pooled sensitivity of 84% and 
specificity of 97% for MRE detecting active terminal ileitis in pediatric CD using 
ileocolonoscopy as reference [121]. Magnet resonance imaging is also very helpful for 
the diagnosis of perianal inflammatory bowel disease, allowing specific differentiation 
between perianal abscess and different types of fistula [123]. In order to evaluate small 
bowel parts, using MRE was superior to video capsule endoscopy but these two 






1.6 Treatment of IBD 
The primary aim of pediatric IBD treatment is to induce and maintain long-lasting 
remission while reducing possible therapy side effects. Induction treatment for children 
with CD involves exclusive enteral nutrition (EEN), steroids or biologics [106]. 
Maintenance treatment for CD patients includes immunomodulators, biologics, and in 
selected cases surgery [106] (fig 5). This thesis will focus on treatment with exclusive 
enteral nutrition, partial enteral nutrition (PEN) and biologics.  














1.6.1 Exclusive enteral nutrition as induction therapy 
The efficacy of exclusive enteral nutrition was discovered by chance almost 50 years 
ago by surgeons who used an elemental diet, created for astronauts, to stabilize 
malnourished IBD patients before bowel surgery. They discovered coincidentally, that 
severely ill CD patients, who have been treated with elemental diet, experienced weight 
gain and improved clinically [124]. EEN is a liquid formula containing protein (whole 
protein, peptides or only amino acids), lipid, carbohydrates, trace elements, and 
















Biologics: anti-integrin agents 
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food than water [78, 126, 127]. According to all major societies (ECCO, ESPGHAN, 
NASPGHAN and ESPEN) EEN is the first- line induction therapy for pediatric CD 
patients with active luminal disease to induce remission. EEN induces clinical 
remission in up to 80%-90% of patients [99, 106, 128-131]. According to previous 
systematic reviews and meta-analyses, EEN is equipotent to induce clinical response 
in PCD compared to corticosteroids [132-137]. Patients with EEN-induced remission 
presented a higher rate of mucosal healing compared to patients treated with 
corticosteroids, evaluated by endoscopic findings [135, 138]. EEN treatment is highly 
demanding; therefore, induction treatment with partial enteral nutrition (PEN) has been 
studied. However, EEN remains superior compared to PEN in inducing remission 
(10/24 [42%] vs .4/26 [15%], respectively, p = 0.035) [139]. The study from Lee et al. 
supported the same effect on EEN vs. PEN in CD children [140].  
1.6.1.1 New strategies with PEN to optimize EEN treatment 
Recently, Crohn’s disease exclusion diet (CDED) has been described. The diet 
excludes processed food, gluten, most dairy products and is based on fresh nutrients. 
The diet was combined with PEN of a complete liquid formula based on casein [127, 
141]. CDED is divided into two phases. Phase 1 includes 50% of energy intake from 
the liquid formula and 50% from CDED. Followed by phase 2 with 25% formula and 
75% CDED of energy intake [142]. CDED requires mandatory nutrients: chicken, eggs, 
banana, potatoes and optional nutrients: rice, strawberries, avocado, tomato, 
cucumbers ect. [57]. CD-TREAT, a study from Glasgow, developed an individualized 
food-based diet. This diet provides similar composition to EEN and was designed 
gluten-and lactose-free with macronutrients, vitamins, minerals, and fiber using 
ordinary food, plus substituting Maltodextrin, an artificial glucose polymer that occurs 
in EEN as the most common carbohydrate [143]. Five children with CD received CD-
TREAT, out of these four (80%) showed clinical response and three (60%) entered 
remission with significant decreases in FC (mean decrease 918 ± 555 mg/kg; 
P=0.002). The study’s overall conclusion implicates CD-TREAT diet reduced gut 
inflammation (evaluated by FC) and replicated EEN changes in the microbiome [143].  
1.6.2 Biologics treatment 
Biologics became a new potent treatment option for IBD patients within the last two 





anti-tumor-necrosis factor alpha agents (anti-TNF-alpha) infliximab (IFX), adalimumab 
(ADA), certulizumab or golimumab, followed by the second group of anti-integrin 
agents: natalizumab - anti integrin alpha 4, vedolizumab - anti integrin alpha 4/beta 7, 
and the newest development: anti interleukin 12/interleukin 23 agent: ustekinumab 
[144]. In children and adolescents with CD only infliximab and adalimumab have been 
licensed. This thesis will focus on treatment with anti-TNF-alpha in CD children. 
Infliximab is a chimeric protein that contains mouse-derived amino acids and it was 
licensed for CD in 1998 [145]. According to European consensus guidelines for 
pediatric CD patients, the indication of anti-TNF-alpha treatment is given in children 
with chronically active luminal CD despite prior optimized immunomodulatory therapy 
or in cases of active steroid-refractory disease to induce remission [106]. Further 
indications for anti-TNF-alpha treatment as first line therapy are active perianal disease 
in combination with surgical intervention and severe extraintestinal involvement [106]. 
Contraindications for treatment with anti TNF alpha drugs are patients with heart failure 
(NYHA III/IV), with evidence of active tuberculosis, uncontrolled HIV infection , 
endemic mycosis, multiple sclerosis or acute infection with Clostridium difficile or 
cytomegalovirus [146].  
1.6.2.1 Drug monitoring and dosing of anti-TNF-alpha treatment 
Therapeutic drug monitoring of biologics is essential for treatment optimization and 
reduces the risk of developing complications in PIBD. Dose adjustment in PCD patients 
with suboptimal trough levels and/or development of anti-drug antibodies lead to a 
significantly increased rate of clinical remission, fewer patients with loss of response 
and to fewer complications in PCD patients [147-151]. The use of concomitant 
immunomodulatory treatment with methotrexate or azathioprine reduces the formation 
of antibodies, therefore less immunogenic response and better drug response [152]. 
For pediatric CD patients IFX infusions should be given with a dose of 5 mg/kg body 
weight at weeks 0, 2, 6, followed by maintenance therapy with 5 mg/kg every 8 weeks 
[106]. There is increasing evidence that children with a body weight below 30 kg or 
those with low albumin serum levels need higher doses up to 10 mg/kg and/or shorter 
administration intervals for induction therapy. The same is true for patients losing 
response to IFX because of low drug level. For mucosal healing a trough level for IFX 
should be > 5 µg/ml, in case of perianal fistula up even around 12 µg/ml [153]. A similar 





treatment for patients >40 kg starts with 2.4 mg/kg, followed by 1.2 mg/kg after 2 
weeks, continued with 0.6 mg/kg every two weeks. Patients <40 kg treatment regime 
is 80mg, 40mg and 20mg every two weeks [106]. CD patients with ADA through level 
>8.5 µg/ml present a better response compared to earlier suggested cut-offs (>5 µg/ml) 
[147]. Weekly injections should be considered in patients with a trough level <8.5 µg/ml 
or losing response.  
2. Objectives of the thesis  
This present thesis is based on two studies, (1) retrospective data analyses and (2) an 
interventional non-randomized controlled trial. Both studies were published in peer-
reviewed journals. I have co-authored in two further publications in the ImageKids trial, 
which are not considered for this thesis. Both have been published in the Journal for 
Pediatric Gastroenterology, and listed under my publications.  
 
▪ Publication I: “Incidence and risk factors for perianal disease in pediatric 
Crohn's disease patients followed in CEDATA-GPGE registry” (published in J 
Pediatr Gastroenterol Nutr. 2018 Jan; 66(1):73-78; PMID: 28604511) 
▪ Publication II: “Partial enteral nutrition has no benefit on bone health but 
improves growth in pediatric patients with quiescent or mild Crohn’s disease 
“(accepted for publication in Clin Nutr. J., April 2020) 
 
The aim of this thesis is to increase the understanding of the development of short- 
and long-term complications in children with IBD and to gain insights into potential risk 
and preventive factors in order to overcome these complications. CD patients are more 
likely to experience complications during the course of the disease compared to 
patients with ulcerative colitis (UC). We will primarily focus on CD patients and highlight 







3. Summary  
Paper I: “Incidence and risk factors for perianal disease in pediatric Crohn's disease 
patients followed in CEDATA-GPGE registry” 
Patients are adversely affected by perianal fistulas and abscesses while suffering from 
secretion and pain [93, 154]. There is limited knowledge on perianal disease in 
pediatric CD patients with respect to basic epidemiologic data, diagnostic, and 
therapeutic management. The first paper aimed to evaluate the prevalence, incidence 
during follow up, risk factors for developing perianal disease, and PD management in 
a large PCD cohort. Data was obtained from the CEDATA-GPGE registry, which is a 
multicenter registry for pediatric IBD patients in Germany and Austria, established by 
the German Society for Pediatric Gastroenterology and Nutrition (GPGE). Additional 
questionnaires were sent to participating CEDATA sites to collect data on current PD 
treatment strategies in Germany. Our data analyses revealed a 5.5% prevalence of PD 
in newly diagnosed CD patients (N=742) and a cumulative incidence of 10% within the 
first three years after diagnosis. Male patients have a three times greater risk for the 
development of PD compared to girls and should be monitored closely. The use of 
steroids increased the risk of developing PD, whereas rectal disease involvement had 
no influence.  According to our additional collected data via questionnaire only 57% of 
affected patients (N=46) had received a complete diagnostic workup for PD (pelvic flor 
MRI plus lower endoscopy with examination under anesthesia) as recommended in 
the international guidelines [155]. 
 
Paper II: “Partial enteral nutrition has no benefit on bone health but improves growth 
in pediatric patients with quiescent or mild Crohn’s disease “ 
Impaired bone health, decreased muscle mass, and delayed growth and pubertal 
development are common complications and difficult to treat in pediatric patients with 
Crohn’s disease (CD). Patients with active CD present a low trabecular and cortical 
density at initial CD diagnosis, growth delay is an ongoing complication during disease 
follow up [97]. Exclusive enteral nutrition (EEN) has been shown to improve nutritional 
status and bone health and induces growth in pediatric CD [17]. Exclusive nutrition with 
complete formula is highly demanding and therefore EEN is not considered as long-





The second paper prospectively evaluated the use of partial enteral nutrition (PEN) 
providing 25% of daily energy intake for 12 months to improve bone and muscle 
development and to support growth in pediatric patients with quiescent CD. In this non-
randomized controlled intervention study including 41 patients, PEN improve bone-
muscle geometry over the 12 months intervention compared to the control group. 
However, we observed a trend for improved muscle cross sectional area and improved 
grip strength. This suggests that PEN may improve the nutritional status in pediatric 
CD patients with an increased lean body mass. The second aim of this study 
addressed the question whether PEN improves growth velocity in patients with 
quiescent disease activity. We found that in patients with well-controlled inflammation 
PEN over 12 months led to catch up growth those with a potential to grow at early 
stage of puberty (Tanner stages ≤3). Furthermore, we evaluated the effect of PEN on 
the intestinal microbiome and plasma metabolome and detected small effects on the 
microbial ecosystems but changes in the composition of the plasma metabolome. 
However, the proof of this affect requires further investigations in larger cohorts. Partial 
enteral nutrition did not have any adverse effects, was well accepted and could be 
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Background and Aims: Perianal disease (PD), comprising fistula and abscess, is a 
severe complication in Crohn’s disease (CD). We examined prevalence, incidence and 
risk factors for PD development in a pediatric CD cohort. 
Methods: CD patients from the prospective, multi-center registry CEDATA-GPGE for 
pediatric inflammatory bowel disease (IBD) in Germany and Austria were included if 
diagnosed ≤18 years, registered within three months of diagnosis and having at least 
two follow-up visits within the first year of registration. We examined potential risk 
factors for PD with Kaplan-Meier analysis and a final cox model considering sex, family 
history of IBD, extraintestinal manifestations, disease localization, induction therapy 
(corticosteroids or nutritional therapy).  
Results: Of 2406 CD patients, 742 fulfilled inclusion criteria (59% male, mean age at 
diagnosis 12.4 ± 3.4 years). PD was present at diagnosis in 41 patients (5.5%; 80.9% 
male) while 32 (4.3%, 81.3% male) developed PD during follow up (mean 2.0 ±1.6 
years). The cumulative incidence of PD 12 and 36 months after diagnosis was 3.5% 
and 7.5%, respectively. Potential risk factors for PD development during follow up were 
male sex (HR=3.2, [95%; CI 1.2-7.8]) and induction therapy with corticosteroids 
(HR=2.5 [1.1-5.5]). A guideline conform diagnostic work up for PD was performed in 
60%. In half of the patient’s PD resolved after one year. 
Conclusion: About 10% of CD patients in our cohort suffer from PD within the first 
three years of their disease. Male sex and initial corticosteroid-therapy were 
associated with increased risk to develop this complication after diagnosis.  
 
 






What is known/what is new: 
What is known: 
• Perianal disease defined as fistula and abscess formation is a serious 
complication and difficult to treat  
• The reported prevalence of perianal disease in newly diagnosed pediatric CD 
patients varies from 8% to 15%, only few data on incidence after diagnosis are 
available. 
• Corticosteroids do not induce mucosal healing in Crohn’s disease.  
What is new: 
• Prospective data on prevalence perianal disease, incidence during follow up 
and potential risk-factors in pediatric Crohn’s disease in a large cohort. 
• Male sex being associated with a three times higher risk for developing perianal 
disease. 
• Use of corticosteroids as induction therapy after diagnosis was found to be 
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Perianal disease (PD) with fistula and abscess formation is a serious clinical problem 
in patients with Crohn’s disease (CD). Perianal fistulas are the most common 
manifestation of fistulising CD.1,2 The development of PD can appear at any time during 
the course of disease and may be the initial manifestation leading to the diagnosis of 
CD.3 Patients with PD suffer from pain and secretion. Fecal incontinence can be a long-
term risk. The reported prevalence of PD in newly diagnosed pediatric CD patients 
varies from 8% to 15%.4,5,6 Long term adult data on the cumulative incidence of PD in 
CD cohort from the US and New Zealand shows that 20-28% developed PD within 20 
years.2,3  The European Crohn’s and Colitis Organization (ECCO) - guidelines 
recommend a full diagnostic assessment in all pediatric CD patients presenting with 
PD and to tailor treatment accordingly.7 Therapeutic options especially for 
transsphincteric or complex fistulas are very limited. Treatment often comprises of a 
combination of pharmaceutical and surgical measures and depends on the 
inflammatory activity, localization and course of PD.8 The identification of risk factors 
would allow choosing the best treatment to reduce the risk of this serious complication 
and provide stratification options for screening and patient education. Limited long-
term data are available in pediatric CD patients on the incidence of PD after diagnosis, 
potential risk factors, management and outcome. 
The primary objective of this project was to examine the prevalence of PD at initial CD 
diagnosis, the incidence during follow up and to determine potential risk factors for the 
development of PD in an unselected group of pediatric CD patients followed in the 
CEDATA-German Society for Pediatric Gastroenterology and Nutrition (GPGE) 
registry. A secondary aim was to investigate whether physicians in Germany and 






Materials and Methods 
We retrospectively analyzed data of CD patients that were entered into the 
German/Austrian registry CEDATA-GPGE within three months after diagnosis and 
followed prospectively, between April 2004-April 2014.The CEDATA-GPGE registry is 
a prospective, multi-center registry for pediatric IBD patients in Germany and Austria, 
established in 2004 by the GPGE. The 96 reporting institutions range from large 
Universities with >200 IBD patients to small regional hospitals.9 Data were collected 
by two standardized questionnaires: one at baseline and one at follow-up visits with at 
least two documentations per year.  
Reporting physicians were asked to complete the Baseline Case Report Form (CRF) 
and the first follow up CRF at the time of patient inclusion into the registry. The Baseline 
CRF includes general patient characteristics, onset and type of symptoms before 
diagnosis, date and type (CD, UC, IBD-U) of final diagnosis, extraintestinal 
manifestations and family history for IBD. The follow up CRF comprises data since the 
last documented visit on medical history including symptoms, stool behavior and 
extraintestinal manifestations, anthropometrics, physical examination including 
perianal findings, laboratory parameters, diagnostic findings (endoscopy, histology, 
imaging), surgical procedures, disease localization and severity, complications (fistula, 
abscess, stenosis and other), comorbidities, and treatment (antibiotics, IBD-specific 
drugs, vitamins, and supplements). Exclusive enteral nutrition as treatment option was 
only assessed from 2008 onwards in the registry. 
Between 2004 and 2013, the institutions submitted patient’s data via hard copy CRFs 
and since August 2013 until censoring of the data for this analysis in April 2014 online 





2010 and August 2013, while previously entered patients continued to have follow up 
CRFs.  
Eligibility 
For this study we included only CD patients fulfilling the following criteria: age at initial 
CD diagnosis ≤18 years, registry enrollment within three months after CD diagnosis, 
submission of at least two follow up CRFs in the first year with a maximum time gap of 
200 days between baseline and first follow up CRF, between the consecutive follow 
up CRFs Eligible patients were censored if the time interval between the consecutive 
follow up CRFs after the first year was >200 days. 
Definitions 
Perianal disease (PD) was defined as perianal fistula and/or perianal abscess 
visualized during clinical examination or imaging. According to the perianal findings, 
we characterized three groups of patients: 
1.) Patients with PD at initial diagnosis had a documented PD in the first CRF 
(prevalence at diagnosis; group 1). 
2.) Patients developing PD during the course of disease had no PD documented in first 
CRF and a documented PD thereafter (incidence of new PD after diagnosis; group 2) 
3.) Patients without PD had no documentation of PD in any CRF (no PD; group 3). 
Family history of IBD included any occurrence of inflammatory bowel disease (IBD) in 
biological relatives of the patient. Extraintestinal manifestations comprises skin 
manifestations (erythema nodosum, pyoderma gangrenosum), fever (>38.5 Celsius >3 
days without other focus), hepatobiliary (primary sclerosing cholangitis (PSC), 





ophthalmological complications, arthralgia or arthritis of peripheral joints and the spine. 
Disease localization was defined according to the Paris classification with separate 
recording of rectal involvement.10 Exclusive enteral nutrition therapy (EEN) was 
considered as exclusive feeding with a balanced elemental or whole protein formula 
for at least 4 weeks. Corticosteroids as initial therapy included prednisolone, 
methylprednisolone, or budesonide given orally, intravenously, and rectally. 
Immunomodulators included azathioprine, 6-mercaptopurine and methotrexate.  
A complete diagnostic workup for suspected PD included pelvic MRI or trans-anorectal 
ultrasonography, colonoscopy or proctosigmoidoscopy, and manual examination 
under anesthesia by a colorectal surgeon.7 
The diagnostic latency was defined as time between the age at onset of symptoms and 
the age of diagnosis. Physician’s global assessment and a weighted pediatric Crohn’s 
disease activity index (wPCDAI) were incompletely available at CD diagnosis and 
therefore not considered in our analysis. 
 
Additional questionnaire for PD management and treatment 
For all identified PD patients fulfilling the inclusion criteria, a questionnaire was sent to 
the respective institutions to confirm and provide additional information, particular 
regarding initial induction therapy, diagnostic and therapeutic management and 
outcome of PD during follow up. 
 
Statistical Considerations 
Descriptive analyses of the cohort and the three patients’ subgroups were given as 
percentages with mean ± standard deviation (SD) or median (min; max) where 





group comparison. Time until event was calculated by time in months from diagnosis 
of CD to first follow-up with documented PD, and in case of non-event censored by last 
follow-up. Kaplan Meier curves were performed and show the survival distribution 
function of the event (PD). The cumulative incidence is the difference of the curve to 1 
and involved only patients with developing PD during follow up. Kaplan Meier curves 
were applied for the comparison of incidental PD cases and patients without PD, to 
identify potential risk factors for the development of PD such as sex, positive family 
history for IBD, extraintestinal manifestation at diagnosis, age at initial CD diagnosis, 
rectal disease involvement at diagnosis, disease location and corticosteroids or EEN 
within the first 3 months as induction therapy. For the comparison of Kaplan Meier 
curves the non-parametric Log Rank test was selected. For multiple analyses Cox 
proportional hazards models were applied and hazard rate ratios were calculated. To 
identify the potential risk factors, a backward selection was used starting with the 
previously by Kaplan Meier estimates recognized (Log Rank with p-value < 0.05) 
potential risk factors, which fulfilled the proportional hazard assumption. Before starting 
selection procedure all possible pairwise interactions were tested. The final model was 
found by stepwise backward elimination, decision by Wald Chi-square or by clinical 
importance. The statistical significance was defined as P < 0.05. Items with missing 
values of more than 30% were not considered as variable in our analysis. The 
statistical software SAS Enterprise for Windows, Release 9.2 (SAS Institute, Cary; NC) 
was used for this study.  
Ethical Statement  
The ethical commissions of the respective participating institutions approved the 





(starting at age 6) and their parents before inclusion. All data were submitted in a 
pseudonymized form with respective data security regulations being followed. 
Results 
In total, 4240 IBD patients, reported by 96 clinical institutions, were included in the 
CEDATA-GPGE registry until March 2014 (55.1% male, median age at diagnosis of 
13.7 years (range 0.3-22.9), 2406 patients were diagnosed with CD (58.4% male; 
median age at diagnosis 13.9 years; range, 0.2-22.9). Of the CD patients, 742 fulfilled 
all inclusion criteria and were reported by 70 of 96 participating clinical institutions, 
(Figure 1). Basic characteristics of this final cohort are summarized in table 1, stratified 
for PD status.  
Out of the 742 patients, 41 (5.5%) had a PD documented at initial CD diagnosis. 
Further 32 patients (4.3%) developed this complication after initial diagnosis. Of these 
73 affected patients, 55 were identified with a perianal fistula, 33 with a perianal 
abscess and thereof 15 patients who were affected by both. 
The cumulative incidence of new PD development during follow up within the first 12 
months after CD diagnosis was 3.5% and until 36 months 7.5%. Most patients (90.0%; 
N=32) developed PD within the first 1.5 years of initial diagnosis. The median time of 
developing PD after initial CD diagnosis was 0.7 years (range, 0.2-4.6). Including 
patients with PD at diagnosis, the cumulative incidence of PD at 1 year after CD 
diagnosis was 9%. 
Table 1 shows the patients characteristics in the different subgroups. Boys were more 
likely to be affected by PD than girls (p=0.006). Rectal inflammation at initial diagnosis 
was more frequent in patients with presence of PD at initial CD diagnosis (70.7%, 





and to patients without PD (49.4%, n=669, p=0.01). There were no differences among 
the patient groups regarding disease localization, age at diagnosis and positive family 
history for IBD.  
Induction therapy used in the three subgroups and the total cohort is shown in table 2. 
More than half of patients in the cohort (55.6%) were initially treated with 
corticosteroids with a higher proportion in patients developing PD during follow up 
(75.0%; p=0.02). EEN therapy was applied in 80 out of 335 (23.9%) patients enrolled 
after 2008 and in 4/10 of patients developing PD during follow up. Azathioprine was 
induced more often in patients with developing PD than in those without PD (62.5% 
vs. 37.8%; p=0.0007). 
Log rank tests in Kaplan Meier indicated the following two variables as potential risk 
factors for developing PD: male sex (log-rank=7.6; p=0.006) and the initial induction 
therapy with corticosteroids (log-rank=5.5; p=0.018), (Figures 2a, 2b).  
No significant associations with later PD were found for positive family history of IBD, 
extraintestinal manifestation, rectal disease localization and age at initial CD diagnosis. 
In a backward selection of the multiple Cox proportional hazards analysis, the effects 
of male sex and induction therapy with corticosteroids steroids were confirmed as 
significantly related to PD development. Testing for pairwise interactions between the 
given variables in the cox regression, no modification effect was found.  
Hazard rate ratios of the resulting risk factors revealed that the risk of developing PD 
was three times higher in males than in females (HR=3.2, [95%; CI 1.2-7.8]). Induction 
therapy with corticosteroids within the first three months of diagnosis was associated 







Management of PD 
The additional questionnaire on PD management was returned by 46 of 73 PD 
patients, thereof 32 were diagnosed with PD at initial CD diagnosis. A complete 
diagnostic workup was performed in 57% (N=46): MRI in 67%, a sigmoidoscopy or 
colonoscopy in 82% and an anal sonography in 10% of patients. Information from the 
additional questionnaire confirmed the registry data, that two thirds of patients with PD 
developing after diagnosis were treated with steroids as induction therapy (74%, 
N=46). After diagnosis of PD, a wide variety of drugs were initiated with half of the 
patients receiving antibiotics and/or Aza/6MP each, another 26% biologicals, mostly 
infliximab, and 19 % received systemic steroids. More than half of the patients (52.2%) 
underwent surgical interventions. Out of them, 17 patients had an abscess incision, 
nine fistula incision, four drainage with seton insertion, and six patients had at least 
two of those interventions combined. One patient received a colostomy. After one year 
of PD occurrence complete healing was reported in half of the patients (51%), 25% 
recovered between one and two years, 12% after two years. In the remaining 12% of 
patients, PD did not resolve until the end of this survey. Of those, three patients 
received biologics in combination with rectal steroids or with Aza/6MP and one of them 
also had a surgical intervention with drainage. Another patient was treated with 
antibiotics, Aza/6MP, nutrition therapy and drainage, and the last patient had no 
medical treatment but abscess incision. Information on relapses after initial healing 
was available in 37 from 46 patients. Of these patients, 19% had relapses. Four 
patients received antibiotics combined with Aza/6MP or methotrexate, one infliximab 
combined with Aza/6MP and antibiotics, one only Aza/6MP and another one did not 







In this pediatric cohort of 742 newly diagnosed CD patients, about 10% suffer from PD 
within the first three years after CD diagnosis. Boys had a three times higher risk for 
developing PD than girls. The use of corticosteroids as induction therapy after 
diagnosis was associated with the development of PD during follow up.  
Our cohort seems representative with similar age and sex distribution compared to all 
CD patients in the registry. The male dominance is in concordance with figures 
reported from a large international prospective European registry (EuroKids) of 1221 
newly diagnosed patients with IBD of which also 59% of the CD patients were boys.11  
To avoid bias, we excluded patients with enrollment more than three months after initial 
CD diagnosis or less than two follow up documentations in the first year. The 
prevalence of PD at diagnosis (5.5%) is lower compared to the reported prevalence of 
9% from the EuroKids registry.10 Keljo et al. revealed a 10% prevalence of PD (perianal 
fistula and abscess) at diagnosis in 287 newly diagnosed pediatric CD patients, 
prospectively collected from the Pediatric IBD Collaborative Group.12 A selection bias 
of more complicated cases reported from large IBD centers cannot be excluded.  In 
contrast, our patients were diagnosed in 70 reporting sites including small hospitals 
and practices. A varying diagnostic latency due to different access to health care 
resources and specialists in the different countries may also explain differences in the 
cohorts. Our data revealed an incidence of 9.0% at one year, including prevalent cases 
at CD diagnosis. Data from Guptas et al. reported a similar incidence of penetrating 
disease of 8.2% at 12 months after diagnosis in pediatric CD patients from the US 
(N=939), also including patients with the event at diagnosis.13 However, this cohort 
focused on penetrating complications and not only on perianal abscess and fistula. 





to 28% cumulative incidence of developing PD within 20 years of initial CD diagnosis, 
including patients with PD at diagnosis.2,3  Since no long-term data from pediatric onset 
CD on the development of PD are available it remains unresolved if age of onset has 
an influence on developing this complication over time. Our data did not show any 
association between age at initial diagnosis and PD within the pediatric range.  
Disease localization did not differ between patients with PD at diagnosis, PD 
developing during follow up and no PD. Our data showed that a high percentage (71%) 
of patients with PD at diagnosis had rectal involvement which is in agreement with 
previous studies in adults.1 However, no significant difference was found between 
children who developed PD during follow up and the remaining patients with no PD 
(both 47%). We also found no association with family history for IBD and the presence 
or absence of PD. Extraintestinal manifestations (EM) at initial diagnosis occurred in 
29% of our cohort which is similar to other pediatric CD studies reports.  14,15,16 No 
significant association between extraintestinal manifestation and PD development was 
seen in our data.  
In our cohort, male pediatric CD patients had a three times greater risk for developing 
PD than girls. We found corticosteroids as initial induction therapy to be associated 
with doubling the risk for developing PD in pediatric patients. Pediatric guidelines for 
CD recommend either corticosteroids or exclusive enteral nutrition as induction therapy 
in moderate to severe CD. More than half of the cohort received systemic 
corticosteroids as induction therapy. It is likely that corticosteroids may have been used 
as initial therapy in children with more severe initial manifestation, and therefore this 
association would be more a marker for disease severity than a causal factor. The 
higher frequency of azathioprine treatment in patients with PD may point in the same 





assessment) at diagnosis were incomplete and did not allow adjustment for 
corticosteroids and azathioprine in our analysis. 
It has been shown that corticosteroids are not inducing mucosal healing compared to 
EEN and anti-TNF-alpha agents. 17,18,19 Therefore, they are a theoretical risk factor for 
infections including abscesses.  Although it is biological plausible, only randomized 
intervention trials will prove a cause relationship if early treatment with corticosteroids 
is a risk factor for development of PD. Since EEN was assessed in our registry only 
after 2008 with only 23.9 % of them receiving it as induction therapy (N=80/335) we 
were not able to estimate its potential effects on PD development.  
The additional survey on PD management showed that Infliximab (IFX) therapy was 
rarely used as initial therapy. The drug was licensed in September 2007 for children 
who had failed corticosteroids and other immunosuppressant drugs. At the time of 
license, almost 50% of the cohort was included.  These legal limitations may explain 
why only 26% of children with PD received biologicals, which are now recommended 
as first line therapy in conjunction with surgical interventions (drainage of abscess, 
seton placement).20 Antibiotics were the most commonly used medications for the 
treatment of PD while surprisingly 20 % received steroids.  
In contrast to previous publications, the strength of this study was the prospectively 
collected patients’ follow up data since 2004 with a high number of unselected newly 
diagnosed CD patients submitted by different types of clinical settings ranging from 
small standard care hospitals to university clinics.  
The estimation of the cumulative incidence is limited due to short patient follow up data 
with a median of 1.6 years. Another limitation was the fact that we could include neither 





assessment into our final cox regression model due to an incomplete reporting of 
relevant data.  
In spite of these limitations, our data are relevant for the management of pediatric CD. 
Since the majority of incident PD occurred within the first 18 months of follow up close, 
monitoring regarding PD development is warranted after diagnosis in pediatric CD 
patients, particularly boys.  Further data are needed to decide whether initial induction 















Patients with PD 
developing during 
follow up  
(Group 2) 
Patients with 
no PD  
 
(Group 3) 
All patients  
 (N=40-41) (N=30-32) (N=661-669) (N=733-742) 
Age at diagnosis 
(mean ±SD) 12.3  ± 2.6 13.4  ±2.8 12.4  ± 3.5 12.3  ± 3.3 
Male in % 78.1* 81.3* 56.6 59.0 
Follow up time in the 
registry in years                         
(median, range) 1.4 (0.09-6.0) 1.6 (0.2-7.0) 1.1 (0.09-7.1) 1.2 (0.1-7.3) 
Positive family history 
for IBD in % 12.2 15.6 17.0 16.6 
Extraintestinal 
manifestation within 
first 3 months of 
diagnosis in % 24.4 40.6 28.7 28.9 
Disease localization 
at baseline (Paris 
classification) in %      
L1 2.4 9.4 6.9 6.7 
L1L4 2.4 3.1 4.6 4.5 
L2 4.9 12.5 13.3 12.8 
L2L4 19.5 9.4 8.2 8.9 
L3 17.1 9.4 22.1 21.3 
L3L4 39.0 40.6 28.8 29.9 
L4 2.5 0 1.2 1.2 
Not available 12.2 15.6 14.9 14.7 
Rectal manifestation 
within first 3 months 
of diagnosis 70.7* 56.3 49.4 50.9 
Diagnostic latency in 
years (median, range) 0.4 (0.0-3.8) 0.3 (0.0-5.6) 0.4 (0.0-9.0) 0.4 (0.0-9.0) 






Table 2: Induction therapy in pediatric Crohn’s disease patients  
Induction therapy  
(within 3 month after 
diagnosis) in % 
Patients 




Patients with PD 
developing 












Exclusive Enteral Nutrition 
from Jan 2008, N= 10-335) 27.3 40.0 23.3 23.9 
Corticosteroids 65.9 75.0* 54.1 55.6 
Antibiotics  58.5** + 18.8** 12.2 15.1 
Methotrexate 0.0 6.9 0.0 1.5 
Immunomodulator (Aza/6MP) 63.4* 62.5* 37.8 40.3% 
Infliximab  2.5 3.5 1.8 1.9 
*Significant <0.05 versus group 3; ** Significant <0.0001 versus group 3; + Significant <0.05 group 1 






















4240 IBD patients 
included into the CEDATA-Registry 
742 CD patients following 
inclusion criteria  
669 without 
PD 
41 with PD at initial 
diagnosis 
2406 Crohn’s disease patients 
32 with PD during 
follow up  
 
73 with PD 
1664 patients excluded (no 
documentation available 






Figure 2a: Kaplan Meier of development PD stratified by sex in pediatric CD patients 
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Kaplan Meier Figure 2a 






Figure 2b: Kaplan Meier of development PD stratified by induction therapy with 
corticosteroids within the first three months after diagnosis in pediatric CD patients over 
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Kaplan Meier Figure 2b 
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Background and aims: Exclusive enteral nutrition induces remission, improves bone 
health and growth in paediatric Crohn’s disease (CD) patients, but is highly demanding 
for patients. We investigated efficacy of partial enteral nutrition (PEN) on bone health, 
growth and course in CD patients and assessed microbial and metabolic changes 
induced by PEN.   
Methods: We performed a two centre, non-randomized controlled intervention study 
in quiescent CD patients aged <18 years. Patients in intervention group received a 
liquid formula providing ~25% of daily energy for one year. At baseline, after 3, 6, 9 
and 12 months, we collected data on bone, muscle (peripheral quantitative 
computertomography), anthropometry, disease activity (weighted paediatric CD 
activity index), metabolomic profile (liquid chromatography mass spectrometry), and 
faecal microbiome (16S rRNA gene sequencing). 
Results: Of 41 CD patients, 22 received the intervention (PEN) (mean age 15.0 ± 1.9 
years, 55% male), 19 served as controls (non-PEN) (12.8 ± 3.1 years, 58% male). At 
baseline, mean bone quality was comparable to reference population with no 
improvement during the intervention. Relapse rate was low (8/41, PEN 4/22 and non-
PEN 4/19, ns). PEN was not associated with microbiota community changes (beta 
diversity) but significantly reduced species diversity. Metabolome changes with 
upregulation of phosphatidylcholines in PEN patients are likely related to lipid and fatty 
acid composition of the formula. PEN significantly improved growth in a subgroup with 
Tanner stage 1-3. 
Conclusion:  In our cohort of paediatric CD patients, PEN did not affect bone health 
but improved growth in patients with a potential to grow.  
 
Keywords: Paediatric inflammatory bowel disease, enteral nutrition, bone and muscle 






Crohn’s disease (CD) during childhood and adolescence puts normal growth and 
development of the musculoskeletal system at risk (1). Impaired bone health, 
sarcopenia and growth deficits are frequently observed at diagnosis. Despite 
improvements after therapy initiation, sustained deficits persist. Therefore, additional 
strategies to improve these outcomes are warranted (2-4).  
In paediatric CD patients, the bone development is disturbed and characterized by low 
trabecular and high cortical bone density, often along with reduced muscle mass (5). 
Consequently, paediatric CD patients may be at increased risk of osteopenia and 
potentially osteoporosis later in life (6). Furthermore, growth delay affects around 15-
40% of patients with paediatric-onset CD at diagnosis and negatively impacts on final 
adult height (7). Both, bone deficits and growth stunting have been attributed to 
inflammatory cytokines, malnutrition and use of corticosteroids. In addition, reduced 
muscle mass and low physical activity are risk factors for impaired bone health as 
mechanical loads are crucial for an appropriate development of bone strength (8).  
Exclusive enteral nutrition (EEN) is a highly effective treatment for inducing remission 
in paediatric CD patients, with a favourable adverse effect profile (9, 10). EEN provides 
improved nutritional supply thereby contributing to correcting micronutrient and caloric 
deficiencies. The beneficial effect on growth has been demonstrated in retrospective 
as well as in prospective studies (11-13). Furthermore, a small prospective study with 
newly diagnosed CD patients showed improved bone and muscle parameters after 8 
weeks of EEN therapy (11). The exact mechanisms of action of EEN in CD remains 
unclear. We and others have shown that EEN is associated with changes in microbial 
signatures but causality behind these changes in the microbial ecosystems on 
outcomes has not been established (14-18).  
Due to the highly demanding adherence to exclusive formula feeding, EEN is not 
considered a long-term maintenance treatment. Other forms of dietary intervention 
have been evaluated, including partial enteral nutrition (PEN) or cyclic EEN. In a 
retrospective study, Wilschanski et al. reported that nocturnal supplementary enteral 
nutrition provided to patients after achieving remission improved linear growth and 
prolonged remission (19). A Canadian prospective study used intermittent elemental 
EEN one out of four months and demonstrated significant height and weight gain in 





consensus guidelines considered intermittent courses of EEN or PEN as potentially 
beneficial for paediatric CD patients with impaired growth (10). More recently, two 
novel dietary interventions have been reported, including CD exclusion diet with PEN 
(21-23) and an ordinary food-based diet replicating EEN (24) but long-term efficacy so 
far has not been established.  
We aimed to determine whether PEN without exclusion diet improves bone and muscle 
development as well as growth in a prospective cohort of paediatric CD patients with 
quiescent or mild inflammation. We also explored the effects of PEN on intestinal 





MATERIAL AND METHODS 
Study design  
We performed a two centre, non-randomized controlled intervention study in CD 
patients aged 6-19 years who were in remission (wPCDAI<12.5) or had mild disease 
activity (12.5≤ wPCDAI ≤40) based on mathematically weighted paediatric Crohn’s 
Disease Activity Index (wPCDAI) (25). The study was originally designed as 
randomized controlled trial. However, during the recruitment of the first patients it 
turned out that randomization to PEN or control was not feasible due to individual 
patients’ strong preferences based on their previous experience with the formula (“I 
liked it” or “I hated it”). Therefore, we changed the design to a non-randomized 
controlled trial two months after study start to achieve inclusion of a sufficient number 
of patients in each arm. Patients were recruited between 02/2016 and 03/2017 in the 
Departments of Paediatric Gastroenterology of the two University hospitals in Munich 
(LMU Munich and Technical University Munich). Patients were offered PEN with a 
casein based complete liquid formula (Modulen® IBD, Nestlé, Frankfurt/Main, 
Germany) that substituted ~25% of daily energy intake for 12 months in order to 
improve bone and muscle parameters. Patients accepting this offer represent the 
intervention group. The control group received no nutritional intervention. All IBD 
patients received recommendations on a healthy and balanced diet (26) as part our 
routine clinical care at time of IBD diagnosis. Both groups continued their medical 
maintenance treatment. Patients were evaluated at baseline and after 3, 6, 9 and 12 
months. Adherence with PEN was followed by regular prescription of formula and PEN 
intake was evaluated at each visit by study team. Patients were asked to provide 3-
days food records for the three days prior baseline, visit month 6, and visit month 12.  
Food records were analysed by a nutritional scientist with the software PRODI® expert 
6.5 (Nutri-Science Stuttgart, Germany). 
The primary endpoints of this study were improvement of bone and muscle parameters 
assessed by peripheral quantitative computer tomography (pQCT) and growth 
(improvement of z-scores for height). The latter was restricted to patients with growth 
potential defined as pre- or early puberty equivalent to Tanner 1-3 at study inclusion. 
Secondary endpoints included changes in disease activity, inflammatory parameters, 
microbiota composition, plasma metabolites and number of relapses. Relapse was 





parallel rise in systemic or faecal inflammation markers (CRP, ESR and/or calprotectin) 
suggesting relapse and/or additional step up medication.(25) 
The original and amended study protocol was reviewed by the Ethical Committees of 
LMU Munich (Nr. 690-15) and Technical University Munich (316/16 S), and by the 
Federal Office for Radiation Protection (Z 5-22462/2-2016-030). Written informed 
consents of patients’ parents/caregivers and age-appropriate informed consents of 
patients have been obtained. The study was registered at the German Clinical Trials 
Registry (Nr. DRKS00010278).  
Anthropometry  
Patients’ height was measured with a stadiometer. Weight was quantified in underwear 
on a calibrated scale. Tanner stages in females (27) and males (28) were assessed by 
treating physicians. Z-scores for height and BMI were calculated based on reference 
data from the World Health Organization (29). Malnutrition was defined by decreased 
z-scores for BMI (undernutrition) and height-for-age (stunting) and classified as mild 
(z-scores −1 to −1.9), moderate (z-scores −2 to −2.9), and severe (z-scores ≤ −3) (30). 
Bone and muscle parameters, grip force 
Data on bone and muscle parameters were assessed by peripheral quantitative 
computed tomography (pQCT, XTC-2000 scanner, Stratec, Pforzheim, Germany) at 
baseline, 6 and 12 months as described by Werkstetter et al. (5). In brief, 
measurements were performed at the non-dominant forearm with the scanner 
positioned at 4% and 65% of the forearm length: trabecular density (at 4% forearm 
length, distal radius: TrbD4), cortical density and thickness (at 65% forearm length, 
proximal radius: CtD65 and CTth65) and muscle-cross sectional area (at 65% forearm 
length: muscleCSA65). With a voxel size of 0.4 mm, 2 mm thick single tomographic 
slices were measured at both positions (distal radius and proximal radius). The 
software (V 5.50; Stratec) processed images and performed calculations. Results were 
expressed as age- and sex-specific z-scores based on reference data from 296 healthy 
German children and adolescents from Neu et al. (31). As the muscleCSA65 depends 
on body height and some patients showed growth retardation, muscleCSA65 was 
corrected for height (32).  
Maximal isometric grip force of the non-dominant hand was measured by an 





matched z-scores were calculated based on reference data from the German DONALD 
(Dortmund Nutritional and Anthropometric Longitudinally Designed) study (33). 
Metabolomics 
Plasma samples for metabolomics were stored at -80°C until measurement. A range 
of 454 metabolites comprising polar lipids (acylcarnitines (Carn), phospholipids (PL) 
including diacyl-phosphatidylcholines (PCaa), acyl-alkyl-phosphatidylcholines (PCae), 
sphingomyelins (SM), acyl-lysophosphatidylcholines (LPCa), alkyl-
lysophosphatidylcholines (LPCe)), sum of hexoses (H1), amino acids (AA), non-
esterified fatty acids (NEFA), keto-acids, and tricarboxylic acid (TCA) cycle metabolites 
were measured using an established high throughput liquid chromatography mass 
spectrometry (LC-MS/MS) platform, as previously reported (34-38). A formula CX.Y 
was assigned for polar lipids and NEFA where X: length of carbon chain, Y: number of 
double bonds, OH: indicates presence of hydroxyl group. Letters ‘a’ & ‘e’ indicate that 
the acyl chain is bound via an ester or ether bond to the backbone, respectively. 
Concentrations were calculated in µmol/l.   
High-throughput 16S ribosomal RNA (rRNA) gene sequencing 
Faecal samples were collected at home in stool collection tubes with DNA stabilizer 
(STRATEC Molecular, Germany) (39) after detailed patient instructions. Collected 
faecal material was immediately submerged in DNA stabilizer and sent at ambient air 
by mail to our department (average time 2 days). Upon arrival samples were 
immediately stored at -80C degree until analysis. Metagenomic DNA was extracted 
from faecal samples using a modified version of the protocol by Godon et al (40). In 
brief, a buffer containing salt solution was added to faecal samples, and incubated for 
one hour at 70°C. Sterile silica beads (500 mg, 0.1 mm glass beads, Roth) were used 
for mechanical lysis of bacterial cells using a FastPrep®-24 bead beater (MP 
Biomedicals) fitted with a 24 x 2 mL cooling adaptor (3 × 40 seconds at 6.5m/s). After 
heat treatment (95°C, 5 min) and centrifugation (15.000 x g, 5 min, 4°C), supernatants 
were treated with RNAse (0.1 µg/µL) for 30 min at 37°C. Metagenomic DNA was 
purified using NucleoSpin® gDNA cleanup kit (Macherey-Nagel) following the 
manufacturer’s instructions. Concentrations and purity were controlled using the 
NanoDrop® system (Thermo Scientific) and samples were stored at 4°C during library 





The V3/V4 region of 16S rRNA genes was amplified (25 cycles) from 24 ng of 
metagenomic DNA using the bacteria-specific primers 341F and 785R (41) followed 
by a 2-step procedure to limit amplification bias (42). Amplicons were purified using 
the AMPure XP system (Beckmann), pooled in an equimolar amount and sequenced 
in paired-end modus (PE275) using a MiSeq system (Illumina Inc.) following the 
manufacturer’s instructions and a final DNA concentration of 10 pM and 15 % (v/v) 
PhiX standard library. 
Sequence analysis 
Raw sequence reads were processed using IMNGS (www.imngs.org) (43), a platform 
based on UPARSE (44). First, all reads were trimmed to the position of the first base 
with quality score <3 and then paired. The resulted sequences were size filtered 
excluding those with assembled size <300 and >600 nucleotides. Paired reads with 
expected error >3 were further filtered out and the remaining sequences were trimmed 
by 10 nucleotides on each side to avoid GC bias and non-random base composition. 
For each sample, sequences were de-replicated and checked for chimeras with 
UCHIME (45). Sequences from all samples were merged, sorted by abundance, and 
operational taxonomic units (OTUs) were picked at a threshold of 97% similarity. 
Finally, all sequences were mapped back to the representative sequences resulting in 
one OTU table for all samples. 
Only those OTUs with a relative abundance above 0.5% total sequences in at least 
one sample were kept to avoid analysis of spurious OTUs. The most detailed 
taxonomic classification for each OTU was assigned by RDP classifier (46) and SILVA 
(SILVA Incremental Aligner) (47). A phylogenetic tree was constructed using the 
Maximum Likelihood method in MEGA6 (48). Sequence proportions per sample were 
normalized to the mean sequence depth. For estimation of diversity within samples 
(alpha-diversity), the Shannon index was calculated and transformed to the 
corresponding effective number of species as described by (49). Effective species 
counts reflect better the true diversity within samples when compared with metrics like 
species richness as they are less affected by the number of rare species. For 
quantification of distances between microbial profiles (beta-diversity), generalized 
Unifrac distances (50) were computed and visualized by Metric Multidimensional 





generated by IMNGS, a fully modular R-based pipeline (Rhea) was used for analysis 
of microbial profiles (51).  
Power and Sample size calculation  
Based on a previous intervention study from our group, we assumed an increase in 
muscleCSA65 of +0.5 z-scores as a measurable improvement by the intervention (11). 
To reject the null hypothesis, we needed to study 18 children in each group with a type 
I error probability of 5% and a power of 80%. 
Statistics 
Descriptive analyses of this cohort were given as percentages with mean ± standard 
deviation (SD) or median and range according to distribution. Basic characteristics 
between the two groups were analysed with unpaired t-tests, while paired t-tests were 
applied for comparisons between different time points within a group. Mann-Whitney 
U test or t-test were applied for group comparison, depending on distribution of the 
data. Categorial data were evaluated by Fisher's exact test. Kaplan Meier curves were 
performed and show the relapse-free survival distribution for both groups. Time until 
event (relapse) was calculated by time in days from study entry. Statistical analyses 
were performed in the R programming environment 3.6.1 for Windows, statistical 
software SAS Enterprise for Windows, Release 9.2 (SAS Institute, Cary; NC) or 
GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla California 
USA, www.graphpad.com). For all tests, p-values below 0.05 were considered to be 
indicative of significant effects (* p<0.05, ** p<0.01, *** p<0.001). 
As for microbiome analysis, PERMANOVA test was performed to determine 
statistically significant differences between groups for beta diversity analysis and 
Kruskal–Wallis rank sum statistical test was applied to determine differences between 
groups for measuring species richness. For visualization of the separation between 
bacterial profiles, multiple dimensional scaling plots were computed using the 
packages vegan and ade4. 
As for metabolomics, data sets from multiple batches were initially preprocessed for 
quality control-based signal drift correction using the statTarget® package (52). The 
following parameters were applied: (a) missing value filter: 0.4; QC span: 0; degree: 2; 
imputation method: multiple imputation using K nearest neighbor (KNN method); 





were computed including ∑PC, ∑PCaa, ∑PCae, ∑lyso.PCa, ∑lyso.PCe, and ∑SM. 
Additionally, ratios between some metabolite species were computed including: (a) 
Σlyso PCa / ΣPCaa, a lipid biomarker of inflammation.(53) (b) ΣPCaa / ΣPCae, 
reflecting oxidative stress(54) (c) ∑PC / ∑SM as indicator of membrane fluidity in 
IBD(55) (d) Carn ratios (Carn 16:0/free carnitine and Carn 2:0 / Carn 16:0) as markers 
of carnitine palmitoyl transferase-1 activity (CPT1) and fatty acid beta-oxidation, 
respectively (56). Finally, 439 metabolites were used for further statistical analysis.  
Considering the complex composition of data involving repeated measurements from 
assays where subjects of each group are exposed to different treatments (PEN/non-
PEN), a multilevel multivariate approach combined with sparse partial least squares 
discriminant analysis (splsda) was applied. A two-factor splsda model was built within 
the mixOmics package (57) to assess differences between the treatment groups at 
different time points. To eliminate any baseline differences, relative concentrations 
were used to build the model, which were calculated by dividing the metabolites 
concentration data for the subsequent time points (3, 6, 9 and 12 months) by the 
respective baseline concentrations. For model optimization, a tuning process using M-
Fold cross validation (CV) was carried out for selection of parameters giving the best 
model performance (number of principal components (PC) and key metabolites to keep 
in each PC (keep X)). Accordingly, three PC were selected accounting for 80% of the 
explained variance with keep X of 50, 30 and 20 key metabolites for the PC 1:3, 
respectively. For a splsda multilevel two-factor analysis, the tuning criterion is based 
on the maximization of the correlation between the components on the whole data set. 
To visualize pairwise associations between the treatment groups and the investigated 
metabolites, a pairwise similarity matrix was computed for the first three spls 
dimensions and then displayed in clustered image maps (CIM) and relevance 









Out of 54 screened CD patients, 42 patients were recruited to the study. Screening 
failures were due to patients refusing study participation, unknown disease activity or 
anticipated difficulties to attend appointments due to long distance travel. Among the 
42 participants, 22 patients agreed to PEN, and 20 patients served as controls (non-
PEN). One patient in the non-PEN group transferred care to a different hospital after 
baseline visit and was therefore excluded from further analysis (Fig. 1A). The 
remaining 41 individuals were comparable for sex, BMI, height, disease location, 
concomitant medication and disease activity, with 37 patients in remission and 4 with 
mild activity (wPCDAI 17.5 – 27.5 points) (Table 1). Time since diagnosis did not differ 
between groups, but patients in the PEN group were diagnosed at a later age and 
therefore older at study inclusion (Table 1). Seven patients in the PEN group and two 
in the non-PEN group had previously been treated with systemic corticosteroids.  
During follow-up, disease activity measurements including wPCDAI, CRP, ESR and 
faecal calprotectin did not differ between PEN and non-PEN patients (Supplemental 
Figure S1). Overall, during 12 months follow-up, four relapses occurred in each group 
(Fig. 1B). PEN was well-tolerated with no adverse effects.  
Bone and muscle parameters, grip strength 
Of 41 followed patients, pQCT measurements of 2/19 patients in non-PEN group and 
of 1/22 patients in PEN were excluded due to technical reasons. At baseline, z-scores 
for trabecular bone density (TrbD4), cortical bone density (CtD65) and muscle cross 
sectional area (muscleCSA65) did not differ between groups (Table 2 and Fig. 2A-C) 
(N=38). Means of TrbD4 and CtD65 centred around zero but muscleCSA65 and grip 
strength were decreased compared to reference values in both groups (Table 2) 
(N=38). Over 12 months follow-up, PEN did not affect TrbD4 or CtD65 (Table 2 and 
Fig. 2A-B). We observed a trend for increase in z-scores for muscleCSA65 corrected 
for individual height and age (muscleCSA65height) in the PEN group after 12 months 
intervention compared to non-PEN (delta z-score +0.39 vs +0.11 respectively, p=0.22, 
N=34) (Fig. 2C). The grip strength only improved in the PEN group, but not significantly 
to the non-PEN group (p=0.26) (Fig. 2D and Table 2). Adherence to provide 3-days 





data from 22 patients (11 each in PEN and non-PEN) who delivered thoroughly 
completed diaries at baseline and at 6 months (N=19) or at 12 months, if the 6 months 
diary was missing (N=3). No significant differences were seen at baseline between the 
two groups for intake of energy, protein and calcium (all calculated as % of 
recommended dietary intake (RDI) for sex and age group), and for vitamin D ( g/day). 
After at least 6 months in the study, patients in the PEN group showed a significant 
increased intake of calcium and vitamin D compared to baseline and a trend for higher 
calorie intake, while children in the control group did not improve their intake over time 
(Supplementary Figure S4). 
Anthropometry in children with growth potential 
To assess the effect of PEN on patients with a potential to grow, we analysed 
anthropometry in a subgroup of children with Tanner stage 1-3 at study inclusion 
(20/41), 10 patients each in the PEN (PENT1-3) (Tanner stage 1, N=5; Tanner stage 3, 
N=5) and in the non-PEN (non-PENT1-3) (Tanner stage 1, N=5; Tanner stage 3, N=5) 
group. Delayed skeletal maturation as assessed by x-ray of the left hand was present 
in 8/10 in PENT1-3 and 6/10 in non-PENT1-3. At baseline, PENT1-3 patients were 
significantly older compared to non-PENT1-3 patients (p<0.01, N=20, Table 1) and 
showed a trend for lower height z-scores compared to non-PENT1-3 individuals (p=0.07, 
N=20, Table 1). Stunting as defined by height-for-age z-scores of less than -2.0 was 
present in only one patient in PENT1-3 group. Over the 12 months follow up, one patient 
in the PENT1-3 group ended study participation after 3 months, due to PEN 
incompliance. In the remaining cohort of 9 PENT1-3 patients, z-scores for height 
improved significantly from baseline to months 12 compared to those 10 non-PENT1-3 
patients (delta of z-scores height 0-12 means:  PENT1-3: 0.45±0.24 vs non-PENT1-3 
0.15±0.16; p=0.005, N=19) (Fig. 3A). Z-scores for BMI were significantly different at 
baseline, with higher BMI values in non-PENT1-3 controls (p=0.02, N=20, Fig. 3B). More 
patients in the PENT1-3 group had BMI z-scores between -1 to -2 indicating mild 
underweight (1/10 non-PENT1-3 vs 8/10 in PENT1-3, p =0.006, Supplementary Table 1). 
Although, those differences remained stable over time and no improvement of BMI z-
scores was observed despite PEN intake (delta of z-scores BMI 0-12 means: PENT1-3: 
0.35±0.29 vs non-PENT1-3 0.2±0.37; p=0.35, N=19) (Fig. 3B), the number of patients 





bone and muscle parameters in this subgroup of patients (N=19) did not reveal 
significant changes over time.  
Microbiome and metabolome 
For16S rRNA gene profiling 164 faecal samples were available from PEN and non-
PEN patients. At baseline, microbial profiles did not differ between both groups (data 
not shown). analysis of pooled follow-up samples (all time points, except for baseline) 
revealed significant but rather small changes in community structure under PEN (Fig. 
4A) but not in control patients, supporting that PEN affects microbial community 
composition (p=0.02). We observed substantial inter-personal variation between 
patients and across their individual disease course irrespective of dietary intervention 
(Fig. 4B). Community diversity at the level of species richness showed a small but 
significant reduction under PEN exposure (Fig. 4C).  
Metabolomics, splsda analysis showed complete separation between the eight 
investigated groups corresponding to the two treatments (non-PEN/PEN) at the four 
time points (3, 6, 9 and 12 months) (Supplementary Figure S2). The CIM plot shows 
two main clusters corresponding to the non-PEN and PEN treatments, each composed 
of four clusters corresponding to the four time points of each treatment group (Fig. 5). 
Remarkable differences were found in the metabolic profiles of the intervention group 
in comparison to the control group, which were majorly persistent throughout the whole 
duration of the study (3, 6, 9 and 12 months). Phospholipids (PL), particularly 
numerous PC species, were consistently either up- or downregulated; however, the 
strongest associations were mostly detected after 3 months intervention. Several PC 
comprising palmitic acid C16.0 namely: PC.aa.32.1, PC.aa.38.4, PC.aa.32.0, 
PC.aa.34.2, PC.aa.36.3 were highly upregulated with the PEN therapy, particularly at 
3 months; although the strongest positive association was obtained for PC.ae.36.1, a 
PC comprising stearic and oleic acids. Similarly, the two investigated Carn ratios and 
Val (AA) were uniformly upregulated in the PEN group, in addition to three NEFA, 
namely: NEFA 14.2; NEFA 15.1; NEFA 18.4 and fumaric acid. On the other hand, 
whether in the non-PEN or PEN groups, some metabolite species behaved differently 
across the four time points. For instance, in the PEN group, 22 metabolites (5 LPC, 5 
SM, 4 Carn; 4 PC, 2 NEFA, glutamine (Glu), and Σlyso.PCa/ΣPCaa ratio) showed an 
initial increase at 3 months similar to the control group before consecutively decreasing 





metabolites, principally phospholipids comprising polyunsaturated fatty acids (PL-
PUFA), increased abruptly at 12 months (Fig. 5). Associations with values higher than 
a selected cut-off (threshold) = 0.5 were also visualized in relevance networks 






Current guidelines suggest PEN as a strategy to improve bone health, sarcopenia, and 
growth development. We prospectively studied the effect of PEN (25% of daily energy 
intake for 12 months) on muscle mass, bone health, and growth in paediatric-onset CD 
patients with quiescent disease activity. Using pQCT, which provides detailed insight 
into changes in trabecular and cortical density and muscle mass, we did not detect any 
change in bone-muscle geometry with PEN over 12 months. CD patients with Tanner 
stage 1-3 may benefit from PEN by improving growth velocity. Furthermore, our results 
revealed that PEN only marginally affects the microbial ecosystems but shapes the 
plasma metabolome.  
Bone and muscle parameters, grip strength 
Poor bone quality in CD has been attributed to several factors, including glucocorticoid 
therapy, ongoing inflammation or nutritional deficiencies. Avoiding systemic steroids 
and controlling inflammation by e.g. anti-TNF therapy improves bone density and 
structure in paediatric CD with greatest effect in younger and growing participants, 
suggesting a window of opportunity for treatment of bone deficits.(59) We have recently 
shown that EEN treatment for 8 weeks improves bone health by week 12 in newly 
diagnosed patients with active CD and impaired bone density and muscle mass.(11) 
In contrast, our present study included children in clinical remission or with mild disease 
activity. Although our patients had a long history of CD, mean z-scores for bone 
parameters at study baseline centred on zero indicating sufficient bone quality at study 
inclusion and adequate anti-inflammatory therapy. The intervention with PEN, did not 
further improve bone parameters, but showed a trend for improved BMI, muscle-cross 
sectional area and grip strength in the PEN compared to the control group. This 
suggests that PEN may improve nutrition in paediatric CD patients and may increase 
lean body mass.  
Growth  
Growth failure has been associated with similar risk factors as bone deficits. Controlling 
CD inflammation by using EEN and/or biologics has been consistently associated with 
stabilized or even improved linear growth, in particular when compared to 
corticosteroid-treated patients (12, 60). Grover et al. demonstrated in a retrospective 





for reducing growth failure (60). In the recently published prospective GROWTH study 
including 147 newly diagnosed paediatric CD patients there was a trend for better 
height z-scores after 2 years follow up in patients receiving EEN compared to steroids 
as initial induction therapy (12). Besides EEN, anti-TNF biologics, both infliximab and 
adalimumab, have been associated with improved growth with patients entering 
remission benefitting most (61, 62). These studies reinforce the concept of avoiding 
corticosteroids and preferring corticosteroid-sparing induction strategies in patients at 
risk for growth failure. Our sub-analysis indicated that the patients with Tanner Stage 
1-3 further benefited from PEN and improved height z-scores over the 12 months 
intervention although they were older compared to controls. Thus, PEN may be offered 
to CD patients in sustained remission but persistent growth deficit.  
Relapse rate/remission maintenance 
Whether PEN improves maintenance therapy in paediatric or adult CD patients and 
reduces relapse rates remains controversial. Yamamoto et al. performed a systematic 
review and concluded that PEN may be useful for maintaining remission in patients 
with medically or surgically induced remission (63). Patients in our study received PEN 
as adjunct therapy in addition to medical maintenance therapy with anti-TNF or 
immunomodulators. We cannot draw any conclusion regarding keeping remission due 
to the low rate of relapses observed over 12 months follow-up. Accordingly, blood and 
faecal inflammatory markers were comparable in both groups during the study period.  
Microbiome 
We have recently shown that EEN is associated with induction of remission and 
substantial shifts in intestinal microbiota (14). In this study, PEN had no consistent 
effect on the intestinal ecosystem. We found substantial changes in microbiome 
profiles of individual patients during follow-up, suggesting an individualized response 
to PEN. In line with previous reports on EEN, we found that PEN also reduces alpha 
diversity. In EEN, the reduction in bacterial richness and alpha-diversity has been 
explained by the absence of dietary fibres, and hence reduction of fermentable 
carbohydrates and luminal microbial density (15-17). Taken together, our data show 
that PEN is not sufficient to drive changes in microbial community structure similar to 







In our analysis, we were able to detect remarkable differences in the metabolome 
following dietary intervention using PEN. This was evident in the complete separation 
of the non-PEN and PEN groups throughout the different time points of the study. Our 
results revealed that PL, especially PC was the species most impacted by PEN, similar 
to previous findings by our group on EEN (64). This was evident in the large number 
of single PC species showing strong association with the PEN therapy, particularly at 
3 months, especially those comprising C16.0. This could be related to the composition 
of the formula used where palmitic acid (C16.0) is the major fatty acid (FA) representing 
>30% of the total formula FA and supports that PEN had direct effects on the 
metabolome of the patients in the intervention group (64). PL may therefore serve as 
a biomarker to assess patient adherence with PEN. We can only speculate about the 
particular strong effect size at month 3 which may be due to highest patient motivation 
and adherence after recruitment.   
An interesting finding is the behaviour of Σlyso.PCa/ΣPCaa ratio. A transient elevation 
at 3 months was seen in both the PEN and control groups, which was followed by a 
consistent decrease in the PEN group in the later time points, unlike the control group. 
Σlyso.PCa/ΣPCaa ratio has been identified as a biomarker of inflammation in previous 
studies (53, 65), and its greater decrease in the PEN than in the control group may 
reflect a greater degree of resolution of inflammation with PEN therapy.  
The principal focus of this analysis was to investigate group differences in the 
metabolome, which was evident in our findings. However, we were also able to detect 
some metabolic changes occurring in patients in remission during the study, apart from 
the intervention. These changes were found in a few PL-PUFA and lactic acid, which 
were relatively stable in both groups throughout the study duration but increased 
remarkably at the end of the study (at 12 months). Our findings strongly hint that 
metabolomics could potentially be indicative of disease activity. 
Study limitations 
Our study has several limitations. First, we were unable to perform this study as 
randomized trial as originally planned as a considerable number of eligible patients 
refused randomization due to individual preferences. Even inclusion of a 2nd IBD centre 





design, we successfully included a sufficient number of patients in each group as 
indicated by our power calculation. Patients’ preferences were neither related to 
gender, socioeconomic background, duration or extend of the disease, nor did we see 
any differences in the adherence to the protocol. However, older patients chose to be 
in PEN group. This resulted in a significant older age at baseline and may have 
introduced a selection bias. Sensitivity analysis of the subgroup with a Tanner stages 
1-3 revealed that those in the PEN group were leaner with a trend for lower height z-
scores. Therefore, we cannot exclude that the increase in muscle CSA in the PEN 
group could also be, at least in part, due to pubertal development. Secondly, only 49% 
(20/41 patients) of our cohort had low Tanner stages 1-3 and therefore had a potential 
for catch up growth. We did not assess parental height in order to correct for mid 
parental height. Further studies in a larger number of patients are required to confirm 
our observation of improved growth velocity during PEN. Thirdly, although we aimed 
to assess accurate food intake with 3-days food records at baseline, and months 6 and 
12, only about 50% of the patients provided food diaries of sufficient quality. However, 
we consider the significant improved intake of certain nutrients in the PEN but not in 
the non-PEN group as indicator for a good adherence to the formula intake. Finally, 
unexpectedly and different from newly diagnosed paediatric CD patients (11), this 
cohort showed a normally distributed bone quality at baseline comparable with the 
healthy reference population. Therefore, the potential for further improving the bone 
parameters was limited. 
In conclusion, our data do not provide evidence that PEN improves bone health in 
adequately treated paediatric CD patients with well-controlled disease activity. Our 
study suggests that PEN may induce catch up growth in CD patients with quiescent 
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Dr Klara Frivolt, a young paediatrician in training at the University of Bratislava, died 
on August 5, 2017 in Hungary being pregnant with her second child. Klara had spent 
two research periods of 18 months each at the Division of Gastroenterology and 
Hepatology at the Dr von Hauner Children’s Hospital, LMU Munich, Germany. She had 
received several research awards including the Nestle Nutrition Award from the 
European Crohn and Colitis Organization (ECCO) in 2014, which she used to conduct 
this study. In a very enthusiastic way she supervised this study as paediatric scientist. 
On July 4, 2017 she successfully defended her PhD thesis. Klara Frivolt was an 
extremely talented young physician, scientist, mother and a wonderful person. We are 
in deep grief. 
We thank the patients who participated in the study and their families for their support. 
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Figure 1. Study design and relapse-free survival. (A) Study design of the non-
randomized controlled intervention study in CD patients aged 6-19 years who were in 
remission or had mild disease activity at inclusion. Patients were evaluated at baseline 
and after 3, 6, 9 and 12 months. (B) Kaplan-Meier survival analysis of relapse-free 






Figure 2. Development of bone and muscle parameters as well as grip strength 
as functional parameter of muscle over time, stratified by group. (A) Analysis of 
trabecular bone density (TrbD4), (B) cortical bone density (CtD65), and (C) muscle 
cross sectional area CSA corrected for height (muscleCSA65height) by pQCT. Grip 
strength was determined by an adjustable-handle Jamar Dynamometer (D). All 







Figure 3. Development of height z-scores in children with Tanner stage 1-3. 
Between baseline and month 12, there was a significant increase in z-scores for height 
in PENT1-3 patients (N=9) but not in the non-PENT1-3 controls (N=10) (A). BMI z-scores 
remained stable in both groups (B). One patient without follow-up was excluded in PEN 
group. Differences in z-scores between baseline and 12 months were calculated for 
individual patients and subsequently significance between groups was assessed by 






Figure 4. Small changes of microbiome signatures mediated through PEN. 
(A) Multidimensional scaling (MDS) plot shows the variance of microbial profiles in the 
intervention group (PEN) and control group (non-PEN). Analysis is based on pooled 
samples from month 3, 6, 9 and 12. (B) MDS plot of randomly-selected 6 patients (3 
patients PEN and 3 patients non-PEN) showing changes in microbial profiles during 
follow-up (baseline, month 3, 6, 9 and 12). Arrows show the transition from each time-
point to the next (Baseline= circles with black lining) (C) Bacterial species richness in 
both groups (PEN and non-PEN) that were analysed from month 3, 6, 9 and 12. (*, 






Figure 5. CIM plot obtained using splsda model with three principal components (PC), 
showing pairwise correlations between the metabolite species and the treatment 
groups (non-PEN/PEN) at the different time points of the study (3, 6, 9, and 12 months). 
The green and red colours indicate positive and negative correlations respectively, 
whereas yellow indicate small correlation values. The treatment groups are clustered 
on the left side of the CIM. Polar lipids and NEFA are represented by a formula X.Y 
where X: length of carbon chain, Y: number of double bonds, OH: indicates presence 
of hydroxyl group. Letters ‘a’ & ‘e’ indicate that the acyl chain is bound via an ester or 





Table 1 Baseline patient characteristics  
 Total cohort (N=41) Subgroup Tanner Stage 1-3 (N=20) 
Baseline patient characteristics   Non-PEN (N=19) PEN  
(N=22) 





Gender (male/female)  11/8 12/10  5/5 4/6  
Age at diagnosis (years)   8.8 ± 3.6 11.8 ± 2.9 0.005 7.6 ± 3.0 10.7 ± 2.5 0.02 
Age at study inclusion (years)  12.8 ± 3.1 15.0 ± 1.9 0.007 10.8 ± 2.7 13.8 ±1.5 0.006 
Tanner Stage 1-3 10/19 10/22  10/10 10/10  
Time (years) of IBD until study inclusion 4.0 ± 2.9 3.2 ± 2.4  0.35 3.2 ± 2.1 3.1 ± 2.0 0.91 
Positive family history  5/19 7/22  4/10 2/10  
Extra-intestinal involvement  4/19 6/22  4/10 5/10  
Disease location  
   
   
   
L1 Terminal ileum  2/19 3/22  0/10 1/10  
L2 Colon    7/19 6/22  5/10 4/10  
L3 Ileocolonic  10/19 13/22  5/10 5/10  
+ L4 (upper GI tract)  17/19 10/22  10/10 5/10  
Disease behaviour   
   
B1 non-stricturing, non-penetrating   18/19 19/22  10/10 8/10  
B2 stricturing 1/19 3/22  0/10 2/10  
B3 penetrating  0/19 0/22  0/10 0/10  
Perianal involvement  7/19 4/22  3/10 4/10  
Therapy at baseline Azathioprine 11/19 10/22  5/10 5/10  
5-Aminosalicylates 4/19 6/22  2/10 3/10  
 Infliximab 12/19 13/22  7/10 6/10  
 Methotrexate  2/19 4/22  2/10 2/10  
 Adalimumab 1/19 0/22  0/10 0/10  
Disease activity Remission (wPCDAI <12.5) 17/19 20/22  10/10 8/10  
Mild disease (wPCDAI ≥12.5 ≤40)  2/19 2/22  0/10 2/10  
Anthropometry Height-for-age z-scores 0.09 ±0.79 -0.08 ±1.14 0.58 0.06 ± 0.72 -0.68 ± 0.96 0.07 
 BMI-for-age z-scores 0.19 ±1.08 -0.38 ±1.12 0.11 -0.16 ± 1.04 -1.23 ± 0.84 0.02 
Data are expressed as mean ± standard deviation. Significant differences are marked in bold. Abbr.: EEN, exclusive enteral nutrition; wPCDAI, 










Mean ± SD  
0 
N=20* / 18 
12 
N= 20* / 18 
Delta 0-12 
N=20* / 18 
0 
N=19* / 16 
12 
N=19* / 16 
Delta 0-12 
N=19* / 16 
P-value (t-Test) 
Diff 0-12 in PEN 
vs. non-PEN 
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